News & Updates
Filter by Specialty:
High glycaemic burden associated with HCC development and fibrosis progression in patients with CHB + T2D
High glycaemic burden is associated with hepatocellular carcinoma (HCC) development and fibrosis progression in patients with chronic hepatitis B (CHB) and type 2 diabetes (T2D) (CHB + T2D), researchers from the University of Hong Kong (HKU) have reported.
High glycaemic burden associated with HCC development and fibrosis progression in patients with CHB + T2D
08 Nov 2022Two-drug dolutegravir-based regimen a valid alternative for pregnant women with HIV
For pregnant women with HIV who are receiving dolutegravir (DTG)-based therapies, the two-drug regimen works just as well as three-drug regimens at keeping the viral load to "undetectable" levels without exerting serious adverse effects on neonatal outcomes, according to a study presented at HIV Glasgow 2022 Congress.
Two-drug dolutegravir-based regimen a valid alternative for pregnant women with HIV
07 Nov 2022Switch to B/F/TAF sustains virologic suppression in adult PLHIV
Adult people with HIV-1 (PLHIV) who switched to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) after initially taking dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) or DTG+F/TAF show a consistently high virologic suppression and have few discontinuations over 5 years of follow-up, according to a study presented at the HIV Glasgow 2022 Congress.
Switch to B/F/TAF sustains virologic suppression in adult PLHIV
07 Nov 2022Statin use linked to reduced risk of severe COVID-19 outcomes
Patients who are on long-term statin therapy may have a reduced risk of severe COVID-19–related outcomes including mortality, intensive care unit (ICU) admission, and requirement for mechanical ventilation, according to a study presented at Anesthesiology 2022.
Statin use linked to reduced risk of severe COVID-19 outcomes
06 Nov 2022Third-dose vaccine beats tolerance in cirrhotic COVID-19 patients
A third-dose administration of a COVID-19 mRNA vaccine results in a more substantial decrease in COVID-19 in patients with cirrhosis compared with the general population, according to a study. This suggests that the third dose can overcome vaccine hyporesponsiveness in this population.